Westpac Banking Corp’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.42M Buy
9,604
+2,716
+39% +$2.08M 0.52% 38
2025
Q4
$5.32M Buy
6,888
+6,073
+745% +$4.12M 0.34% 73
2025
Q3
$458K Hold
815
0.03% 265
2025
Q2
$428K Sell
815
-16
-2% -$8.93K 0.03% 268
2025
Q1
$527K Sell
831
-158
-16% -$109K 0.04% 253
2024
Q4
$704K Hold
989
0.05% 257
2024
Q3
$1.04M Buy
989
+66
+7% +$73.4K 0.07% 226
2024
Q2
$970K Buy
923
+80
+9% +$77.6K 0.08% 198
2024
Q1
$811K Sell
843
-18
-2% -$17.1K 0.06% 219
2023
Q4
$756K Buy
861
+163
+23% +$134K 0.06% 222
2023
Q3
$574K Sell
698
-2,828
-80% -$2.22M 0.04% 290
2023
Q2
$2.53M Sell
3,526
-12,248
-78% -$9.44M 0.18% 153
2023
Q1
$13M Sell
15,774
-3,096
-16% -$2.34M 0.17% 154
2022
Q4
$13.6M Buy
18,870
+9,646
+105% +$7.12M 0.2% 134
2022
Q3
$6.35M Sell
9,224
-405
-4% -$255K 0.1% 276
2022
Q2
$5.69M Sell
9,629
-6,233
-39% -$4.05M 0.07% 336
2022
Q1
$11.1M Sell
15,862
-12,161
-43% -$7.69M 0.13% 220
2021
Q4
$17.7M Buy
28,023
+4,963
+22% +$3.05M 0.18% 137
2021
Q3
$14M Sell
23,060
-9,447
-29% -$5.86M 0.15% 175
2021
Q2
$18.2M Buy
32,507
+7,613
+31% +$3.86M 0.18% 141
2021
Q1
$11.8M Buy
24,894
+9,512
+62% +$4.63M 0.13% 205
2020
Q4
$7.43M Buy
15,382
+939
+7% +$507K 0.08% 305
2020
Q3
$8.08M Sell
14,443
-1,147
-7% -$695K 0.11% 248
2020
Q2
$9.72M Sell
15,590
-4,476
-22% -$2.54M 0.14% 176
2020
Q1
$9.8M Sell
20,066
-2,268
-10% -$936K 0.17% 157
2019
Q4
$8.39M Buy
22,334
+14,896
+200% +$5.01M 0.11% 268
2019
Q3
$2.06M Sell
7,438
-1,510
-17% -$447K 0.03% 512
2019
Q2
$2.8M Buy
8,948
+3,383
+61% +$1.13M 0.04% 403
2019
Q1
$2.29M Buy
5,565
+509
+10% +$210K 0.04% 416
2018
Q4
$1.89M Hold
5,056
0.03% 466
2018
Q3
$2.04M Hold
5,056
0.04% 431
2018
Q2
$1.74M Sell
5,056
-17,892
-78% -$5.6M 0.03% 411
2018
Q1
$7.9M Buy
22,948
+4,992
+28% +$1.74M 0.16% 198
2017
Q4
$6.75M Buy
17,956
+1,000
+6% +$405K 0.15% 192
2017
Q3
$7.58M Buy
16,956
+11,769
+227% +$5.6M 0.17% 183
2017
Q2
$2.55M Sell
5,187
-784
-13% -$343K 0.06% 372
2017
Q1
$2.31M Buy
5,971
+1,230
+26% +$456K 0.02% 539
2016
Q4
$1.68M Hold
4,741
0.02% 503
2016
Q3
$1.91M Buy
4,741
+480
+11% +$193K 0.02% 473
2016
Q2
$1.49M Buy
4,261
+1,001
+31% +$386K 0.02% 545
2016
Q1
$1.18M Sell
3,260
-2,465
-43% -$1.02M 0.01% 529
2015
Q4
$3.11M Buy
5,725
+2,473
+76% +$1.34M 0.03% 387
2015
Q3
$1.51M Buy
3,252
+2,764
+566% +$1.48M 0.02% 480
2015
Q2
$249K Sell
488
-4,227
-90% -$2.06M ﹤0.01% 639
2015
Q1
$2.39M Sell
4,715
-231
-5% -$97.9K 0.02% 480
2014
Q4
$2.03M Sell
4,946
-372
-7% -$146K 0.02% 499
2014
Q3
$1.92M Buy
5,318
+59
+1% +$19.8K 0.02% 503
2014
Q2
$1.49M Hold
5,259
0.01% 545
2014
Q1
$1.58M Buy
5,259
+500
+11% +$154K 0.02% 502
2013
Q4
$1.31M Sell
4,759
-31
-0.6% -$8.92K 0.02% 538
2013
Q3
$1.5M Sell
4,790
-192
-4% -$50.5K 0.02% 495
2013
Q2
$1.04M Buy
+4,982
New +$1.16M 0.02% 546

Other funds holding REGN

Westpac Banking Corp's REGN Position: Q1 2026 in Review

Westpac Banking Corp increased its Regeneron Pharmaceuticals (REGN) stake by 39% in Q1 2026, buying an estimated $2.08M and bringing the position to 9,604 shares worth $7.42M. The position accounts for 0.52% of the portfolio, ranked #38.

Westpac Banking Corp first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.2M in Q2 2021. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Westpac Banking Corp held 9,604 shares of Regeneron Pharmaceuticals worth $7.42M as of Q1 2026.
  • Westpac Banking Corp bought 2,716 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.08M.
  • Regeneron Pharmaceuticals made up 0.52% of Westpac Banking Corp's portfolio in Q1 2026, its #38 holding.
  • Westpac Banking Corp first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Westpac Banking Corp's Regeneron Pharmaceuticals position peaked at $18.2M in Q2 2021.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Westpac Banking Corp's 13F filing for Q1 2026, filed 12 May 2026.